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ABSTRACT
Background: Cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogene-
sis of allergic rhinitis. Pharmacological studies using CysLTs indicate that 2 classes of receptors exist, namely,
CysLT1 and CysLT2 receptors. The former class of receptors is sensitive to the CysLT1 antagonists currently
used to treat asthma and allergic rhinitis, and its localization has been previously examined by our group using
immunohistochemistry and in situ hybridization techniques. We investigated the expression and localization of
the CysLT2 receptor in human nasal mucosa by western blot and immunohistochemical analyses.
Methods: Human turbinates were obtained after turbinectomy from 16 patients with nasal obstruction refrac-
tory to medical therapy. To identify the cells expressing the CysLT2 receptor, double immunostaining was per-
formed by using anti-CysLT2 receptor antibody and anti-CD31 (endothelial cell) antibody or anti-smooth muscle
actin antibody.
Results: A 39 kDa band was detected on the western blots of human turbinates samples by using the anti-
CysLT2 receptor antibody. The expression level of the CysLT2 receptor in patients with nasal allergy was higher
than that in patients with non-allergic rhinitis. The immunohistochemical study also showed an intense im-
munoreactivity for CysLT2 receptor in both vascular endothelial cells and vascular smooth muscles.
Conclusions: The results indicated that the CysLT2 receptor plays a primary role in the vascular responses in
the upper respiratory tract.
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INTRODUCTION
The allergic response is a complex process involving
the interaction of many mediators. Among these me-
diators, cysteinyl leleukotrienes (CysLTs) are impor-
tant for the pathogenesis of airway allergic diseases
such as allergic rhinitis and asthma.1 Pharmacologi-
cal studies using CysLTs indicate that at least 2
classes of receptors exist, namely CysLT1 and
CysLT2 receptors.2,3 Our previous immunohisto-
chemical study showed that anti-CysLT1 receptor an-
tibody labeled eosinophils, mast cells, macrophages,
neutrophils, and vascular endothelial cells in human
nasal mucosa,4 suggesting that in allergic rhinitis, the
major targets of the CysLT1 antagonists are vascular
bed and infiltrated leukocytes.
While the CysLT1 receptor has been studied in
great detail in relation to allergic rhinitis and asthma,1
our knowledge of the CysLT2 receptor function is still
rather limited, which is in part because of the lack of
a specific receptor antagonist. To understand the role
of the CysLT2 receptor in nasal allergy, it is very im-
portant to gather information about the localization of
the receptor. However, few studies have shown the
CysLT2 receptor expression in nasal specimens, spe-
cifically in epithelial cells,5 submucosal glands,6 and
inflmammatory leukocytes.5-7 In the present study,
we performed immunohistochemical analysis on sur-
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Table　1　Demographic characteristics of allergic and non-allergic patients
Allergic rhinitis
N = 10
Non-allergic patients
N = 6
p Value
Sex (male/female) 4/6 3/3 NS
Age 34 ± 16  38 ± 10 NS
Specifi c IgE to house dust mite (d1) (kU/L) 5.3 ± 4.6 <0.35 0.004
Total IgE (kU/L) 331 ± 297 100 ± 61 NS
Blood eosinophils (cells/μL) 441 ± 296 137 ± 57 0.04
Local eosinophils (cells/mm2) 58.2 ± 25.6   9.2 ± 10.7 0.003
Total nasal symptom score (TNSS) 5.8 ± 2.8  2.3 ± 1.0 0.03
Nasal obstruction score 3.2 ± 0.8  1.7 ± 0.8 0.02
Sneezing score 1.7 ± 1.4  0.5 ± 0.5 NS
Rhinorrhea score 1.0 ± 1.3  0.2 ± 0.4 NS
Data expressed as mean ± SD or No. NS, not signifi cant.
gical specimens to demonstrate the localization of
CysLT2 receptor in nasal structural cells. The western
blot analysis also confirmed the up-regulation of the
CysLT2 receptor in perennial allergic nasal mucosa.
METHODS
TISSUE PREPARATION
Human inferior turbinates were obtained after tur-
binectomy from 16 patients with nasal obstruction re-
fractory to medical therapy. Informed consent was
obtained from all patients, and this study was ap-
proved by the ethics committee of Sapporo Medical
University (approval number: 24-14). All patients
were nonsmokers, of which 10 had perennial allergy
to mites as diagnosed by questionnaires and the CAP
test (Pharmacia, Uppsala, Sweden). The remaining 6
patients who had concomitant septoplasty because of
symptomatic nasal septal deviation, with a negative
CAP test for major inhaled allergens such as mites,
birch, grass, mugwort and Japanese cedar were in-
cluded in non-allergic rhinitis group as control. Sever-
ity of nasal symptoms (nasal obstruction, sneezing
and rhinorrhea) was assessed on 0-4 category scale
and Total Nasal Symptom Score (TNSS) was calcu-
lated. All medications, including antibiotics, were pro-
hibited for at least 3 weeks prior to the study. Demo-
graphic and clinical characteristics of the patients are
summarized in Table 1. The nasal mucosal speci-
mens dissected from the cartilage, were either frozen
immediately in liquid nitrogen and stored at -70℃ for
protein extraction or fixed in 10% formalin for immu-
nohistochemistry.
WESTERN BLOT ANALYSIS
The nasal samples were homogenised in the Tissue
Protein Extraction Reagent (T-PER, Thermo Fisher
Scientific, Waltham, MA, USA), supplemented with
the Proteiase Inhibitor Cocktail (Sigma, St. Louis,
MO, USA). Protein extracts were then purified using
the PAGEprepTM Advance Kit (Thermo Fisher Scien-
tific), and protein concentrations in the homogenates
were determined by the BCA Protein Assay Kit
(Thermo Fisher Scientific). Protein extracts (20 μg of
protein each sample) were separated in a 4-12% so-
dium dodecyl sulfate (SDS)-polyacrylamide gels and
blotted onto polyvinylidene difluoride membranes
(Invitrogen, Carlsbad, CA, USA). Membranes were
subsequently blocked and probed with a rabbit poly-
clonal anti-human CysLT2 antibody (1 : 500; ab75160,
Abcam, Cambridge, UK). A rabbit polyclonal anti-
human antibody against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) was also used as an inter-
nal control. The bands were visualized using West-
ernBreeezeⓇ Chromogenic Immunodetection Kit (In-
vitrogen). The ratio of the protein levels of the
CysLT2 receptor to GAPDH was determined by den-
sitometric analysis.
IMMUNOHISTOCHEMISTRY
Deparaffinized sections were initially incubated with
3% H2O2 in methanol for 30 min to quench endoge-
nous peroxidase activity. After microwave treatment
(10 min at 500 W in citrate buffer), the sections were
incubated in blocking solution (10% normal goat se-
rum in PBS) for 30 min before overnight incubation
with the primary antibody at 4℃. A rabbit polyclonal
anti-human CysLT2 antibody raised against a peptide
derived from the first extracellular domain of the hu-
man CysLT2 receptor (ab115453, Abcam) was used
as the primary antibody at a concentration of 10 μg
ml. The sections were washed, and incubated for 30
min with EnVision+, Peroxidase (Dako, Carpinteria,
CA, USA). A further wash in PBS was followed by de-
veloping in DAB (Dako) as a chromogen for signal
visualization. The slides were counterstained with
Mayer’s haematoxylin and mounted on a cover slip
using a mounting medium.
To identify the subsets of cells expressing CysLT2
receptor, the following monoclonal antibodies were
CysLT2 Receptor in Nasal Mucosa
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Fig.　1　A: Western blots showing CysLT2 receptor protein level in allergic 
nasal mucosa (lane 1-10) and nonallergic nasal mucosa (lane11-16). The 
antibody recognized a single, 39-kDa protein -the CysLT2 receptor. B: 
Densitometric analysis of the relative protein level of CysLT2 receptor as 
shown. The data were expressed as mean + SD and normalized to GAP-
DH.
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used: anti-CD31 (JC70A clone, Dako) for vascular en-
dothelial cells, anti-smooth muscle actin (1A4 clone,
Dako) for vascular smooth muscle, and anti-human
CD45 (2B11 + PD726 clone, Dako) for leukocyte
common antigen. For double staining, deparaffinized
sections were incubated overnight at 4℃ with a com-
bination of rabbit polyclonal anti-human CysLT2 anti-
body and one of mouse monoclonal anti-human phe-
notypical maker antibody.
The sections were washed in PBS and incubated
for 30 min with both Alexa Fluor 488-conjugated goat
anti-mouse IgG and Alexa Fluor 594-conjugated goat
anti-rabbit IgG (1 : 50; Molecular Probes, OR, USA).
The sections were mounted using VectashieldⓇ
mounting medium with 4’,6 diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA, USA)
and examined under an Olympus BX51 microscope
fitted with a DP70 CCD camera (Olympus Optical,
Tokyo, Japan). All image analysis was performed with
DP Controller and DP Manager Software (Olympus
Optical). Using this method, the CysLT2 receptor-
expressing cells were visualized as red, vascular en-
dothelial cells were green, and the combined signal
was visualized as yellow.
STATISTICAL ANALYSIS
The protein levels of the CysLT2 receptor and
GAPDH detected in the duplicate experiment of west-
ern blot analysis were determined, and data were pre-
sented as mean ± standard deviation. The non-
parametric Mann-Whitney U test was used to evalu-
ate differences between perennial allergic rhinitis and
control subjects. Values of P 0.05 were considered
to be statistically significant.
RESULTS
WESTERN BLOTTING
To determine the protein size of the CysLT2 receptor
in human nasal mucosa, its expression was examined
by using western blot analysis. As shown in Figure 1
A, a single band of the predicted molecular weight
(approximately 39 kDa) was detected. Densitometric
quantification of the bands was performed to deter-
mine the expression levels of the CysLT2 receptor
and GAPDH in allergic and non-allergic nasal mucosa
(Fig. 1B). The ratio of CysLT2 receptorGAPDH in
nasal mucosa from patients with nasal allergy was sig-
nificantly higher than that from non-allergic patients
(allergic rhinitis: 1.12 ± 0.29, control: 0.60 ± 0.16, p =
0.005). No significant correlation was found between
the level of CysLT2 receptor and nasal symptom
score, total and specific IgE, local and blood eosino-
phil number (data not shown).
IMMUNOHISTOCHEMISTRY
The distribution of the CysLT2 receptor in nasal mu-
cosa was examined by means of immunohistochemis-
try. As shown in Figure 2A, a significant immunoreac-
tivity for the CysLT2 receptor was detected in blood
vessels. In contrast, epithelial cells and submucosal
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Fig.　2　Immunohistochemical staining for CysLT2 receptor in hu-
man nasal mucosa. Inferior turbinates were stained with anti-human 
CysLT2 receptor antibody (A) or normal rabbit immunoglobulin (B). 
CysLT2 receptor immunoreactivity was observed mainly on blood 
vessels (arrow). ep, epithelial cells; g, submucosal glands; v, blood 
vessels. Scale bar = 200 μm.
Fig.　3　Identifi cation of CysLT2 receptor on blood vessels 
of the nasal mucosa. (A): CysLT2 receptor positive cells. (B): 
Anti-CD31 stain as an identifi cation marker for vascular en-
dothelial cells. (C): Overlay image. CysLT2 protein (red) 
shows co-localization with anti-CD31 antibody (green) and 
the combined signal is visualized as yellow. Not only vascu-
lar endothelial cells, but also vascular smooth muscles ex-
press CysLT2 receptor. ep, epithelial cells; g, submucosal 
glands; v, blood vessels. Scale bar = 200 μm.
Fig.　4　Identifi cation of CysLT2 receptor on vascular 
smooth muscle of the nasal mucosa. (A): CysLT2 receptor 
positive cells. (B): Anti-smooth muscle actin stain as an iden-
tifi cation marker for vascular smooth muscle. (C): Overlay 
image. CysLT2 protein (red) shows co-localization with anti-
smooth muscle actin antibody (green) and the combined sig-
nal is visualized as yellow. Vascular smooth muscles ex-
press CysLT2 receptor. g, submucosal glands; v, blood 
vessels. Scale bar = 100 μm.
glands showed little or no expression. Specificity of
the staining was confirmed by the absence of labeling
with normal rabbit immunoglobulin (Fig. 2B). To fur-
ther clarify the vascular cell types expressing the
CysLT2 receptor, double immunofluorescence stain-
ing was performed for CysLT2 receptor (Fig. 3A, 4A)
and for CD31 and smooth muscle actin, which are as
a vascular endothelial cell marker (Fig. 3B) and a vas-
cular smooth muscle marker (Fig. 4B), respectively.
As shown in Figure 3C, 4C, not only vascular endo-
thelial cells but also vascular smooth muscle showed
intense immunoreactivity for the CysLT2 receptor. In
CysLT2 Receptor in Nasal Mucosa
Allergology International Vol 62, No2, 2013 www.jsaweb.jp 227
Fig.　5　Identifi cation of CysLT2 receptor on infl ammatory 
leukocytes in the nasal mucosa. (A): CysLT2 receptor posi-
tive cells. (B): Anti-CD45 stain as an identifi cation for leuko-
cyte common antigen. (C): Overlay image. CysLT2 protein 
(red) shows co-localization with anti-CD45 antibody (green) 
and the combined signal is visualized as yellow. Not only 
blood vessels, but also some infl ammatory leukocytes (ar-
row) express CysLT2 receptor. g, submucosal glands; v, 
blood vessels. Scale bar = 100 μm.
order to clarify the CysLT2 receptor on inflammatory
leukocytes, we performed double immunofluores-
cence staining for CysLT2 receptor (Fig. 5A) and leu-
kocyte common antigen (Fig. 5B). As shown in Fig-
ure 5C, some inflammatory leukocytes express
CysLT2 receptor. The further double immunohisto-
chemical staining revealed that the majority of these
CysLT2 receptor positive cells were mast cells and
macrophages (data not shown). The pattern of the
immunohistochemical findings for all 16 patients
were remarkably similar.
DISCUSSION
The results from this study, obtained nasal surgical
specimens, indicate that the nasal CysLT2 receptor lo-
calizes exclusively in blood vessels. In the past, only
few studies have been designed to explore the ex-
pression of the CysLT2 receptor in nasal mucosa bi-
opsies from patients with allergic rhinitis.5-7 Corrigan
et al. showed the presence of the CysLT2 receptor in
inflammatory leukocytes, mucus glands and epithelial
cells in nasal biopsies from patients with chronic rhi-
nosinusitis.5 On the other hand, the CysLT2 receptor
immunoreactivity in sinus mucosa obtained from en-
doscopic sinus surgery was mainly detected in inflam-
matory leukocytes.6,7 These previous reports did not
examine the expression of the CysLT2 receptor in
blood vessels.5-7 To the best of our knowledge, our
study shows for the first time, the presence of CysLT2
in human nasal blood vessels.
The studies using mice with deletions8 or overex-
pression9 of the CysLT2 receptor in the lungs have
suggested a prominent role for the receptor in medi-
ating vascular permeability. In vitro, human umbilical
vein endothelial cells (HUVECs) express the CysLT2
receptor mRNA in vast excess (>4000-fold) of the
CysLT1 receptor mRNA, and Ca2+ fluxes caused by
CysLTs in HUVECs may result from perturbation of
the CysLT2 receptor rather than the expected CysLT1
receptor.10 Therefore, the CysLT2 receptor-mediated
nasal vascular response may affect nasal vascular per-
meability and consequent plasma leakage may be
cause local tissue edema and watery rhinorrhea.
Moreover, CysLTs have been found to elicit several
specific functional responses in endothelial cells, eg,
the synthesis of platelet activating factor,11 secretion
of von Willebrand factor, and surface expression of P-
selectin.12 These effects may be in part due to activa-
tion of the CysLT2 receptor.
Our present immunohistochemical studies have
clearly shown the expression of the CysLT2 receptor
not only in vascular endothelial cells, but also in vas-
cular smooth muscle cells. With regards to the ex-
pression of the CysLT2 receptor in human vascular
smooth muscle cells, only the presence of its mRNA
in coronary artery has been reported using RT-PCR
and in situ hybridization.13 When human coronary
smooth muscle cells are stimulated with LTC4, the in-
tracellular calcium concentration increases, which
suggests that the contraction induced by LTC4 may
be mediated by the CysLT2 receptor.13 In contrast,
activation of the CysLT2 receptor in endothelial cells
leads the release of a relaxant factor, nitric oxide
(NO).14 Because no data on the experimental model
of allergic rhinitis using CysLT2 receptor-deficient
mice or CysLT2 receptor antagonists, the biological
significance of the CysLT2 receptor in nasal vascula-
ture remains unclear.
The expression of CysLT2 receptor was found not
only on nasal vasculature, but also on some infiltrated
leukocytes such as mast cells and macrophages in
the nasal mucosa. It has been reported that mast
cells, macrophages and eosinophils in nasal lavage
from patients with active seasonal allergic rhinitis ex-
pressed CysLT2 receptor.15 The roles of CysLT2 re-
ceptor in these inflammatory leukocytes still remain
unclear.
Our present western blot analysis has showed that
the expression of the CysLT2 receptor increased sig-
nificantly in allergic nasal mucosa compared to non-
allergic samples. Previous studies on paranasal sinus
mucosa have also shown that the CysLT2 receptor
mRNA expression in chronic rhinosinusitis was sig-
nificantly higher than that in controls.6,7 In addition,
mucosal hyper-responsiveness, a pivotal pathophysi-
ological characteristic of allergic rhinitis has been ob-
served in patients with perennial allergic rhinitis.15 It
is therefore, logical to hypothesize that hyperrespon-
Shirasaki H et al.
228 Allergology International Vol 62, No2, 2013 www.jsaweb.jp
siveness might stem from the up-regulation of the
leukotriene receptors. The CysLT2 receptor expres-
sion is subjected to regulation in vitro. Our previous
study showed that CysLTs and Th2 cytokines such as
IL-13 enhanced the expression of CysLT2 receptor in
human monocytes in vitro.16 Some studies have also
demonstrated increased local levels of IL-4 and IL-13
following allergen provocation in allergic rhinitis.17
Therefore, it is possible that the CysLT2 receptor in
allergic airways may be up-regulated by IL-13 re-
leased from leukocytes.
To further clarify the role of CysLTs in the allergic
airways, a dual CysLT1CysLT2 receptor antagonist
might be more appreciate. However, the pharmacol-
ogy of the CysLT2 receptor is less defined than that of
CysLT1 receptor, mainly because of the lack of a se-
lective antagonist. The dual CysLT1CysLT2 receptor
antagonist BAY u9773 may act as a CysLT1 receptor
agonist.18 Thus, the clinical advantages of dual
CysLT1 and CysLT2 receptor antagonists for the treat-
ment of allergic rhinitis are still unknown.
In conclusion, our results indicate that the CysLT2
receptor plays a primary role in the vascular re-
sponses in the upper respiratory tract. The present
findings should be of considerable interest for eluci-
dating the potential roles of the CysLT2 receptor in
upper airway diseases such as allergic rhinitis.
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